| Literature DB >> 28292438 |
Jason Boyang Wu1, Lijuan Yin2, Changhong Shi2, Qinlong Li3, Peng Duan2, Jen-Ming Huang2, Chunyan Liu2, Fubo Wang4, Michael Lewis5, Yang Wang6, Tzu-Ping Lin7, Chin-Chen Pan8, Edwin M Posadas9, Haiyen E Zhau2, Leland W K Chung10.
Abstract
Metastasis is a predominant cause of death for prostate cancer (PCa) patients; however, the underlying mechanisms are poorly understood. We report that monoamine oxidase A (MAOA) is a clinically and functionally important mediator of PCa bone and visceral metastases, activating paracrine Shh signaling in tumor-stromal interactions. MAOA provides tumor cell growth advantages in the bone microenvironment by stimulating interleukin-6 (IL6) release from osteoblasts, and triggers skeletal colonization by activating osteoclastogenesis through osteoblast production of RANKL and IL6. MAOA inhibitor treatment effectively reduces metastasis and prolongs mouse survival by disengaging the Shh-IL6-RANKL signaling network in stromal cells in the tumor microenvironment. These findings provide a rationale for targeting MAOA and its associated molecules to treat PCa metastasis.Entities:
Keywords: bone metastasis; interleukin-6; monoamine oxidase A; osteoblast; osteoclast; prostate cancer; receptor activator of NF-kB ligand; sonic hedgehog signaling; tumor-stromal interactions; visceral metastasis
Mesh:
Substances:
Year: 2017 PMID: 28292438 DOI: 10.1016/j.ccell.2017.02.003
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743